Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1686993 | 0.85 | KMT2A (0.48) | KMT2AMEN1PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL29532332 | 0.84 | KMT2A (0.47) | KMT2AMEN1PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL29532244 | 0.82 | KMT2A (0.46) | KMT2AMEN1PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL29532383 | 0.82 | HSP90AA1 (0.46) | KMT2AMEN1PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL2280172 | 0.81 | KMT2A (0.54) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL15615933 | 0.81 | KMT2A (0.54) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL776014 | 0.81 | MEN1 (0.67) | KMT2AMEN1PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL30631460 | 0.81 | MEN1 (0.67) | KMT2AMEN1PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL28536823 | 0.80 | TSHR (0.50) | KMT2AMEN1PKMALDH1A1MAPT | |
| SCHEMBL28434345 | 0.80 | APP (0.47) | KMT2AMEN1PKMALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109223779-B | Pharmaceutical composition for promoting fracture healing and preparation method and application thereof | 山东中医药大学 | 2020-07-17 | — | — | CN | claimed |
| US-11427582-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | UWM RESEARCH FOUNDATION, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210047322-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-18 | — | — | US | disclosed |
| US-10865203-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | UWM RESEARCH FOUNDATION, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3325479-B1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | UWM RES FOUNDATION INC (US) | 2020-12-02 | — | — | EP | disclosed |
| CN-109223779-B | Pharmaceutical composition for promoting fracture healing and preparation method and application thereof | 山东中医药大学 | 2020-07-17 | — | — | CN | disclosed |
| EP-3325479-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAa RECEPTORS ANS THEIR METHODS OF USE | UWM Research Foundation, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180134698-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-17 | — | — | US | disclosed |
| EP-2822953-B9 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2822953-B1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9133215-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133215-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680111-B2 | Macrocyclic derivatives for the treatment of diseases | PFIZER INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013132376-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | PFIZER INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| WO-1993017682-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 1993-09-16 | — | — | WO | disclosed |
| US-4996213-A | For treating nervous system disorders | SANOFI (FR) | 1991-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047322-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | GABRA6, HTR6, GABRD | KMT2A 3519/4885MEN1 3061/4885PKM 4246/4885 |
| US-20130252961-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, EML4 | KMT2A 1185/4885MEN1 194/4885PKM 267/4885 |
| US-20180134698-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | GABRA6, HTR6, GABRD | KMT2A 3756/4885MEN1 3268/4885PKM 4378/4885 |
| US-11427582-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | GABRA6, HTR6, GABRD | KMT2A 3519/4885MEN1 3061/4885PKM 4246/4885 |
| US-20140135339-A1 | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES | ALK, ETV6, EML4 | KMT2A 1185/4885MEN1 194/4885PKM 267/4885 |
| US-10865203-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | GABRA6, HTR6, GABRD | KMT2A 3756/4885MEN1 3268/4885PKM 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.